CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $) In Millions, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 1,771	$ 1,656
Marketable Securities, Current	951	1,173
Receivables	3,673	3,083
Inventories	1,640	1,657
Deferred income taxes	2,036	1,597
Prepaid expenses and other	556	355
Total Current Assets	10,627	9,521
Property, plant and equipment	5,236	5,333
Goodwill	7,646	7,635
Other intangible assets	8,176	8,778
Deferred income taxes	195	203
Marketable Securities, Noncurrent	3,623	3,523
Other assets	1,301	904
Total Assets	36,804	35,897
Current Liabilities:
Short-term borrowings and current portion of long-term debt	680	826
Accounts payable	2,466	2,202
Accrued expenses	2,277	2,573
Deferred income	1,003	825
Accrued rebates and returns	1,034	1,054
Income taxes payable	208	193
Dividends payable	611	606
Total Current Liabilities	8,279	8,279
Pension, postretirement, and postemployment liabilities	773	1,882
Deferred income	4,198	4,024
Income taxes payable	739	648
Deferred income taxes	904	383
Other liabilities	665	475
Long-term debt	6,532	6,568
Total Liabilities	22,090	22,259
Commitments and contingencies (Note 17)
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,445 in 2013 and 5,189 in 2012, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2013 and 2012	221	221
Capital in excess of par value of stock	1,966	2,694
Accumulated other comprehensive loss	(2,312)	(3,202)
Retained earnings	32,826	32,733
Less cost of treasury stock - 561 million common shares in 2013 and 570 million in 2012	(17,975)	(18,823)
Total Bristol-Myers Squibb Company Shareholders' Equity	14,726	13,623
Noncontrolling interest	(12)	15
Total Equity	14,714	13,638
Total Liabilities and Equity	$ 36,804	$ 35,897